

Mercy Medical Center
NCCN Guideline Review – Stage III Rectal Cancer

Study Topic: Standard 4.6 – Monitoring Compliance with Evidence-Based Guidelines

Objective: Each calendar year, the Cancer Committee designated a physician member to complete an in-depth analysis to assess and verify that the Cancer Program patients are evaluated and treated according to evidence-based national treatment guidelines. Results are presented to the Cancer Committee and documented in the Cancer Committee minutes.

Measurement: Review of all 2018 Stage III rectal cancer cases to determine compliance with NCCN guidelines

Method: Retrospective chart review

Results:

Staging Workup: Stage III Rectal Cancer Checklist	Compliant	Total	Percent
Biopsy	5	5	
Colonoscopy	5	5	
CBC	5	5	
Chemistry Profile	5	5	
CEA	5	5	
CT Chest	5	5	
CT Abdomen	5	5	
CT Pelvis	5	5	
Pelvic MRI	4	5	
Pre-op chemotherapy & radiation	4	5	
Transabdominal resection	4	5	
Adjuvant chemotherapy	4	5	
Overall Compliance	56	60	93%

Findings/Conclusions:

There were a total of five analytic patients diagnosed with Stage III rectal cancer in 2018. Four patients were diagnosed and received all treatment at Mercy. The other patient was diagnosed via biopsy elsewhere and had surgery elsewhere; however, patient received chemotherapy and radiation at Mercy.

The compliance rate for this study is 93%. Patient #1 had an endoscopic ultrasound rather than a pelvic MRI. This same patient was not a candidate for pre-operative chemotherapy and radiation due to compliance issues. Patient #2 was found to have a second primary, stomach with peritoneal implants, and Hospice was discussed with the patient. Patient #3 did not have a transabdominal resection as patient was found to have a complete response upon repeat sigmoidoscopy and the patient decided on active surveillance as treatment of choice.

Recommendations/Actions:

Information will be shared with Dr. Nelson, Mercy's colorectal surgeon.